In the case of nivolumab and pembrolizumab, which are immune checkpoint inhibitors and can control Mtb by activating CD8+ T cells, several reports have indicated that TB becomes more severe or reactivated in cancer patients treated with these drugs [121,122,123,124]. The gene discussed is CD8A; the disease is tuberculosis.